If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today
Weight loss drugs are big news, and Viking has one in development in both injectable and oral form.
Investors are eagerly awaiting trial results later this year.
10 stocks we like better than Viking Therapeutics ›
Viking Therapeutics (NASDAQ: VKTX) investors have seen a handsome return over the past three years, and this demonstrates that the real battle over biopharmaceutical stocks is won in the lab and clinical trials. Viking Therapeutics doesn't have a commercial product on the market yet and has never generated a dollar in revenue. Yet, it's made many investors wealthy.
One thousand dollars invested three years ago is now worth an incredible $10,640 as of Aug. 11.
Viking Therapeutics: The best may be yet to come
The excitement around the stock centers on its lead development compound, VK2735. It's a GLP-1/GIP dual agonist for the treatment of obesity. Vikings VK2735 is following in the footsteps of Eli Lilly's GLP-1/GIP dual agonist tirzepatide (branded as Zepbound), and investors are hoping VK2735 can achieve similar levels of success.
Where is this promising drug now
VK2735 is in phase 3 trials in subcutaneous (injection) form, with results probably not due until 2027, and, arguably more excitingly, it's in phase 2 trials in an oral form. The latter has obvious benefits of convenience and comfort for patients, and management expects to report on the phase 2 trial this year.
Investors have high hopes, as the phase 2 subcutaneous trial resulted in up to 88% of patients experiencing more than 10% weight loss.
The phase 1 trials in oral form were also impressive (remember that phase 1 trials are fundamentally exploratory and often aim to understand safety and tolerability), with a mean weight loss of 8.2% after 28 days of dosing.
These results are enough to encourage Viking investors that VK2735 could prove to be a hugely successful compound, and the results of the latest tests of the oral form are eagerly anticipated, not least by potential larger pharmaceutical companies that may try to buy the company and take VK2735 (oral) through phase 3.
Should you invest $1,000 in Viking Therapeutics right now?
Before you buy stock in Viking Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!*
Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 11, 2025
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy.
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Big 22: East Lincoln Wide Receiver Jaxon Dollar
East Lincoln's Jaxon Dollar is one of the country's top wide receivers and has the college offers to prove it. >>Click here to check out Channel 9's High School Football Page Dollar, a rising junior, has offers from powerhouse programs like Alabama, Clemson, and Michigan. He is Friday's Big 22 Player to Watch. Dollar is hoping to follow in the steps of his brother, Cam, who is a former Division 1 wide receiver. >> In the video at the top of the page, learn how Dollar is looking to add to his family's athletic traditons. We're profiling 22 players in 2 months for Channel 9's Big 22 throughout August. Tune into Channel 9 each day to see local stars featured. VIDEO: Channel 9's Big 22 players to watch 2025
Yahoo
16 minutes ago
- Yahoo
Hundreds may have been exposed to rabies at bat-infested cabins at Grand Teton National Park
Health officials are working to alert hundreds of people in dozens of states and several countries who may have been exposed to rabies in bat-infested cabins in Wyoming's Grand Teton National Park over the past few months. As of Friday, none of the bats found in some of the eight linked cabins at Jackson Lake Lodge had tested positive for rabies. But the handful of dead bats found and sent to the Wyoming State Veterinary Laboratory in Laramie for testing were probably only a small sample of the likely dozens that colonized the attic above the row of cabins, Wyoming State Health Officer Dr. Alexia Harrist said. Other bats weren't killed but got shooed out through cabin doors and windows. Meanwhile, the vast majority never flapped down from the attic into living spaces. Health officials thus deemed it better safe than sorry to alert everybody who has stayed in the cabins recently that they might have been exposed by being bitten or scratched. Especially when people are sleeping, a bat bite or scratch can go unseen and unnoticed. 'What we're really concerned about is people who saw bats in their rooms and people who might have had direct contact with a bat,' Harrist said Friday. The cabins have been unoccupied, with no plans to reopen, since concessionaire Grand Teton Lodge Company discovered the bat problem July 27. Bats are a frequent vector of the rabies virus. Once symptoms occur — muscle aches, vomiting, itching, to name a few — rabies is almost always fatal in humans. The good news is a five-shot prophylactic regimen over a two-week period soon after exposure is highly effective in preventing illness, Harrist noted. The cabins opened for the summer season in May after being vacant over the winter. Based on the roughly 250 reservations through late July, health officials estimated that up to 500 people had stayed in the cabins. They were trying to reach people in 38 states and seven countries through those states' health agencies and, in the case of foreign visitors, the U.S. Centers for Disease Control and Prevention. Others who have not been alerted yet but stayed in cabins 516, 518, 520, 522, 524, 526, 528 and 530 this year should tell health officials or a doctor immediately, Harrist said. Health officials were recommending prophylactic shots for people who fit certain criteria, such as deep sleepers who found a bat in their room, and children too young to say that they had seen a bat. The Wyoming Department of Health had no ongoing concern about visitor safety at the Jackson Lake Lodge area. That includes a Federal Reserve economic policy symposium Aug. 21-23 that takes place at Jackson Lake Lodge every summer. 'The lodge company has done a fantastic job of doing their due diligence of making sure everyone that is coming in for that, and for all other visits this year, are going to be as safe as possible,' said Emily Curren, Wyoming's public health veterinarian. 'Three or four' dead bats from the cabins tested negative and one that was mangled did not have enough brain tissue to be testable, Curren said. All were brown bats, which come in two species: 'little' and 'big,' with the larger ones more than twice as big. Officials were unsure which species these were, but both are common in Wyoming. They typically live in colonies of 30 to 100 individuals, Curren said. 'That's a lot of bats that we cannot rule out a risk of rabies being in,' Curren said. 'There's no way for us to know for certain about every single bat that got into these rooms.' There are no plans to exterminate the bats, Grand Teton National Park spokesperson Emily Davis said. Devices fitted to the building were keeping the bats from getting back in after flying out in pursuit of insects to eat, they said. Solve the daily Crossword
Yahoo
16 minutes ago
- Yahoo
Trump Wants a Piece of Intel -- And Wall Street Is All Ears
The Trump administration could be gearing up for a bold move: a direct equity stake in Intel (NASDAQ:INTC). According to people familiar with the talks, the potential deal is aimed at reviving Intel's long-delayed factory project in Ohio, once promised to be the largest chipmaking hub in the world. Shares jumped 7.4% to $23.86 on the day of the news and gained as much as another 4% after hours, as the market reacted to the possibility of federal backing. The discussions come just days after President Donald Trump met with Intel's new CEO Lip-Bu Tan, whom he recently criticized for alleged ties to China. While the deal's details are still in fluxand could fall apartany move would signal Tan's job is likely safe for now. Warning! GuruFocus has detected 10 Warning Signs with INTC. This wouldn't be the first time the Trump administration takes a hands-on approach with corporate America. It recently took a 15% cut of certain semiconductor sales to China and secured a golden share in U.S. Steel to help clear a foreign acquisition. Even more surprising? The Pentagon just became the biggest shareholder in MP Materials (NYSE:MP) with a $400 million preferred equity deal. If Intel follows the same playbook, investors could see a blend of equity, guaranteed purchases, and government-led financingsomething the White House sees as a way to crowd in private capital while reassuring markets that the U.S. government has skin in the game. Intel's Ohio site was expected to benefit heavily from the 2022 CHIPS Act, but with funding momentum now uncertain, a direct government stake could change the equation. The factory buildout has already been pushed into the 2030s, and Tan has shifted focus toward stabilizing the company's finances. Earlier this year, one idea floated was to have TSMC (NYSE:TSM) operate Intel's factories under a joint venturebut that plan never advanced. What's unfolding now could become a new chapter in U.S. industrial policy: one where Washington doesn't just regulate or subsidizebut invests, owns, and influences. This article first appeared on GuruFocus. Sign in to access your portfolio
